SonoCloud

Low Intensity Contact Ultrasound Implant 

For Improved Brain Therapy

The treatment of brain tumors using chemotherapy is currently not very effective. One of the major causes is the low penetration of chemotherapeutic agents into the brain due to the blood-brain barrier (BBB).

Many articles in the scientific literature have demonstrated the the blood-brain barrier can be opened using ultrasound in combination with systemic injection of an ultrasound contrast agent. This opening allows for an increased concentration of chemotherapeutic agents in brain tissue. Until now, all of the research in the field has used focused external ultrasound (HIFU) and is limited to small areas in the brain.

Primary brain tumors are often a diffuse disease. The objective of CarThera® is to open a larger zone of the BBB to allow for an optimal penetration of chemotherapy drugs in the brain. In addition, as chemotherapy sessions are performed repeatedly, our ultrasound system is compatible with repeated opening of the BBB in an outpatient setting.

The histological diagnosis or surgical resection of brain tumors requires an opening of the skull. This opening is normally followed by a closing of the skull opening. The idea for the SonoCloud® was to use this opening in the skull to implant an ultrasound device.

 

plug3

“Our primary innovation was to work on a device that emitted unfocused ultrasound from within the skull to avoid distortion of the ultrasound waves and to simplify the technique for repeated treatments. Thus was born the SonoCloud® program” as explained by Pr. Alexandre Carpentier.

 

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    14.10.2016
    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

    15.06.2016
    A world first published in Science Translational Medicine

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in human brain, allowing increased penetration of therapeutic molecules

    Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera
     
    Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders